|
|
|
|
|
|
Sponsored by: |
Memorial Sloan-Kettering Cancer Center |
Information provided by: | Memorial Sloan-Kettering Cancer Center |
ClinicalTrials.gov Identifier: | NCT00658385 |
Betathalassemia major is a disease of the blood and bone marrow. You were born with it and it has made you unable to make normal hemoglobin and red cells. You have been receiving red blood cell transfusions all your life. These transfusions do not cure your disease. The problem with transfusions is that they contain a lot of iron. With time iron builds up in your body and will eventually hurt some of your organs . Because of this buildup of iron , you are taking medicine that helps your body get rid of the extra iron.
Today, the only other treatment is bone marrow or stem cell transplant. It can only be done when a matched donor is available. This is most often a brother, sister, or parent. Bone marrow transplant may cure betathalassemia major. If you have a transplant and it is successful, you will no longer have the disease. Without a matched sibling or parent, the standard treatment is to keep having transfusions.
In the near future, we will be testing a new treatment for making normal hemoglobin and normal red blood cells. We have recreated the healthy hemoglobin gene in a test tube. We are able to use it and put it back into cells. This is called gene therapy. We have been able to put this gene into the stem cells of mice with thalassemia. These mice were cured. We now plan to take that gene and put it into stem cells from people who have betathalassemia major. We will then inject those stem cells back into that person's blood.
In general, we can obtain more stem cells from the blood of a person than from the bone marrow . In order to do so, we must give that person a blood growth factor. The growth factor stimulates the bone marrow to make more stem cells. That growth factor is called granulocyte colony stimulating factor (GCSF), or Filgrastim.
The purpose of this trial is to find out if the drug GCSF has any side effects on you, and if you will make more stem cells in response to it. This trial is not a gene therapy trial. This trial will not help your thalassemia.
Condition | Intervention |
Beta Thalassemia Major Congenital Anemias |
Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis) |
Genetics Home Reference related topics: | beta thalassemia |
MedlinePlus related topics: | Anemia Thalassemia |
ChemIDplus related topics: | Granulocyte colony-stimulating factor |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Pilot Trial to Assess the Feasibility and Safety of GCSF Mobilization of CD34+ Hematopoietic Progenitor Cells in Patients With Betathalassemia Major |
Estimated Enrollment: | 5 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2010 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
|
Genetic: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF. These will be done again 24 hours after your stem cells are collected. |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Farid Boulad, MD | bouladf@mskcc.org | |
Contact: Richard O'Reilly, MD | oreillyr@mskcc.org |
United States, New York | |||||
Memorial Sloan-Kettering Cancer Center | Recruiting | ||||
New York, New York, United States, 10065 | |||||
Contact: Farid Boulad, MD bouladf@mskcc.org | |||||
Contact: Richard O'Reilly, MD oreillyr@mskcc.org | |||||
Principal Investigator: Farid Boulad, MD |
Memorial Sloan-Kettering Cancer Center |
Principal Investigator: | Farid Boulad, MD | Memorial Sloan-Kettering Cancer Center |
Memorial Sloan-Kettering Cancer Center 
  |
Responsible Party: | Memorial Sloan-Kettering Cancer Center ( Farid Boulad, MD ) |
Study ID Numbers: | 08-030 |
First Received: | April 10, 2008 |
Last Updated: | September 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00658385 |
Health Authority: | United States: Institutional Review Board |
|
|
|